Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions
International Journal of Molecular Sciences · 06.09.2023 · 24 (18) · 13726
DOI: 10.3390/ijms241813726 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.09.2023. Verfasst von Cynthia Mark und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Breast Neoplasms. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Department of Defense.
Abstract (Originalsprache)
Antibody drug conjugates (ADCs) are novel medications that combine monoclonal antibodies with cytotoxic payloads, enabling the selective delivery of potent drugs to cancer cells expressing specific surface antigens. This targeted strategy seeks to optimize treatment effectiveness while reducing the risk of systemic toxicity, distinguishing ADCs from conventional chemotherapy. The rapid growth in ADC research has led to numerous developments and approvals for cancer treatment, with significant impacts on the management of breast cancer. ADCs like T-DXd for HER2-low disease and sacituzumab govitecan for triple negative breast cancer (TNBC) have provided valuable options for challenging subtypes of breast cancer. However, essential questions still need to be addressed, including the optimal order of ADCs amidst the growing number of newly developed ones and strategies to overcome resistance mechanisms. Preclinical studies have shed light on potential resistance mechanisms, emphasizing the potential benefit of combinational approaches with other agents such as immune checkpoint inhibitors (ICIs) and targeted tyrosine kinase inhibitors (TKIs) to enhance treatment effectiveness. Additionally, personalized approaches based on molecular profiling hold promise in tailoring ADC treatments to individual tumors, identifying unique molecular markers for each patient to optimize treatment efficacy while minimizing side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
ORCID-Profile: Cynthia Mark, Jin Sun Lee
Förderung
- NCI NIH HHS
- National Institutes of Health
- Department of Defense
- Samuel Oschin Cancer Institute Research Development Fund
Zitieren
APA
Mark, C., Lee, J. S., Cui, X., & Yuan, Y. (2023). Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions. International Journal of Molecular Sciences, 24(18), 13726. https://doi.org/10.3390/ijms241813726
Vancouver
Mark C, Lee JS, Cui X, Yuan Y. Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions. International Journal of Molecular Sciences. 2023;24(18):13726. doi:10.3390/ijms241813726
BibTeX
@article{Mark2023,
author = {Mark, Cynthia and Lee, Jin Sun and Cui, Xiaojiang and Yuan, Yuan},
title = {Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {18},
pages = {13726},
doi = {10.3390/ijms241813726}
}
EUVIMED